Emerging evidence reveals that COVID-19 antiviral therapies may pose severe cardiovascular risks, urging caution in treating vulnerable patients.
Study: Cardiovascular adverse effects of antiviral therapies for COVID-19: Evidence and plausible mechanisms. Image Credit: Corona Borealis Studio / Shutterstock.com
Several antivirals, including remdesivir, Paxlovid, molnupiravir, and monoclonal antibodies like tixagevimab…
